References
- 1. Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35:455-469.10.1093/eurheartj/eht386
- 2. Löfman I, Szummer K, Hagerman I, et al. Prevalence and prognostic impact of kidney disease on heart failure patients. Open Heart. 2016;3:e000324.10.1136/openhrt-2015-000324
- 3. Shiba N, Shimokawa H. Chronic kidney disease and heart failure — Bidirectional close link and common therapeutic goal. J Cardiol. 2011;57:8-17.10.1016/j.jjcc.2010.09.004
- 4. International Diabetes Federation. IDF Diabetes Atlas, 2015. Available at: http://www.diabetesatlas.org
- 5. Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12:73-81.10.1038/nrneph.2015.173
- 6. Roberts AW, Clark AL, Witte KK. Review article: Left ventricular dysfunction and heart failure in metabolic syndrome and diabetes without overt coronary artery disease — do we need to screen our patients? Diab Vasc Dis Res. 2009;6:153-163.
- 7. Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55:2154-2162.10.1007/s00125-012-2579-0
- 8. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29-34.10.1016/0002-9149(74)90089-7
- 9. American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care. 2017;40(Suppl1):S1-S135.10.2337/dci17-000728637893
- 10. Re RN. A Reassessment of the Pathophysiology of Progressive Cardiorenal Disorders. Med Clin North Am. 2017;101:103-115.10.1016/j.mcna.2016.08.00727884222
- 11. Schefold JC, Filippatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016;12:610-623.10.1038/nrneph.2016.11327573728
- 12. Karnib HH, Ziyadeh FN. The cardiorenal syndrome in diabetes mellitus. Diabetes Res Clin Pract. 2010;89:201-208.10.1016/j.diabres.2010.05.02220599286
- 13. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2:843-851.10.1016/S2213-8587(14)70031-2
- 14. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-596.10.1016/j.jacc.2008.05.068285696019215833
- 15. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53:582-588.10.1016/j.jacc.2008.08.08019215832
- 16. Ramos HR, Birkenfeld AL, de Bold AJ. INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist. Endocr Connect. 2015;4:R25-R36.10.1530/EC-15-0018448517726115665
- 17. Farmakis D, Filippatos G, Kremastinos DT, Gheorghiade M. Vasopressin and vasopressin antagonists in heart failure and hyponatremia. Curr Heart Fail Rep. 2008;5:91-96.10.1007/s11897-008-0015-z18765079
- 18. Lekawanvijit S, Krum H. Cardiorenal syndrome: acute kidney injury secondary to cardiovascular disease and role of protein-bound uraemic toxins. J Physiol. 2014;592:3969-3983.10.1113/jphysiol.2014.273078419800824907309
- 19. Rubattu S, Mennuni S, Testa M, et al. Pathogenesis of chronic cardiorenal syndrome: is there a role for oxidative stress? Int J Mol Sci. 2013;14:23011-23032.
- 20. Ma RC. Genetics of cardiovascular and renal complications in diabetes. J Diabetes Investig. 2016;7:139-154.10.1111/jdi.12391477366127042264
- 21. Hundae A, McCullough PA. Cardiac and renal fibrosis in chronic cardiorenal syndromes. Nephron Clin Pract. 2014;127:106-112.10.1159/00036370525343831
- 22. Charytan DM, Fishbane S, Malyszko J, McCullough PA, Goldsmith D. Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. Am J Kidney Dis. 2015;66:196-120.10.1053/j.ajkd.2014.12.016451668325727384
- 23. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818-827.10.1016/j.jacc.2008.04.06118755344
- 24. Young JB, Abraham WT, Albert NM, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol. 2008;101:223-230.10.1016/j.amjcard.2007.07.06718178411
- 25. Battiprolu PK, Gillette TG, Wang ZV, Lavandero S, Hill JA. Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets. Drug Discov Today Dis Mech. 2010;7:e135-e143.10.1016/j.ddmec.2010.08.001302647321274425
- 26. Garud MS, Kulkarni YA. Hyperglycemia to nephropathy via transforming growth factor beta. Curr Diabetes Rev. 2014;10:182-189.10.2174/157339981066614060610364524919657
- 27. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia. 2008;51:714-725.
- 28. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005;16:120-126.10.1016/j.tem.2005.02.00315808810
- 29. Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol. 2016;90:84-93.10.1016/j.yjmcc.2015.12.011471874026705059
- 30. Yilmaz S, Canpolat U, Aydogdu S, Abboud HE. Diabetic Cardiomyopathy; Summary of 41 Years. Korean Circ J. 2015;45:266-272.10.4070/kcj.2015.45.4.266452110326240579
- 31. Aroor AR, Mandavia CH, Sowers JR. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin. 2012;8:609-617.10.1016/j.hfc.2012.06.005345706522999243
- 32. Sweiss N, Sharma K. Adiponectin effects on the kidney. Best Pract Res Clin Endocrinol Metab. 2014;28:71-79.10.1016/j.beem.2013.08.002425256724417947
- 33. Nasrallah MP, Ziyadeh FN. Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Semin Nephrol. 2013;33:54-65.10.1016/j.semnephrol.2012.12.00523374894
- 34. Rüster C1, Wolf G. Adipokines promote chronic kidney disease. Nephrol Dial Transplant. 2013;28(Suppl4):iv8-iv14.10.1093/ndt/gft19124179016
- 35. Ybarra J, Sánchez-Hernández J, Vilallonga R, Romeo JH. Differential associations between glomerular filtration rate and duration of obesity depending on the presence or absence of left ventricular diastolic dysfunction. Eur J Intern Med. 2016;32:47-52.10.1016/j.ejim.2016.02.01626935097
- 36. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891-975.10.1002/ejhf.59227207191
- 37. Fenske W, Athanasiou T, Harling L, Drechsler C, Darzi A, Ashrafian H. Obesity-related cardiorenal disease: the benefits of bariatric surgery. Nat Rev Nephrol. 2013;9:539-551.10.1038/nrneph.2013.14523917797
- 38. Cahn A, Cernea S, Raz I. Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. Rev Endocr Metab Disord. 2016;17:117-127.10.1007/s11154-016-9351-627106831
- 39. Mummidi S, Das NA, Carpenter AJ, et al. Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone+salt-induced cardiac fibrosis in vivo. J Mol Cell Cardiol. 2016;98:95-102.10.1016/j.yjmcc.2016.07.00627423273
- 40. Soraya H, Clanachan AS, Rameshrad M, Maleki-Dizaji N, Ghazi-Khansari M, Garjani A. Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction. Eur J Pharmacol. 2014;737:77-84.10.1016/j.ejphar.2014.05.00324842192
- 41. El Messaoudi S, Rongen GA, Riksen NP. Metformin therapy in diabetes: the role of cardioprotection. Curr Atheroscler Rep. 2013;15:314.10.1007/s11883-013-0314-z23423523
- 42. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007;30:2148-2153.10.2337/dc07-014117536074
- 43. Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol. 2016;8:61-81.10.2147/CPAA.S82008492277527382338
- 44. Aguilar D. Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease: A Clinical Conundrum. Circ Heart Fail. 2016;97pii:e003316.10.1161/CIRCHEARTFAILURE.116.00331627413031
- 45. Pfeffer MA, Claggett B, Diaz R, et al. ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373:2247-2257.10.1056/NEJMoa1509225
- 46. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311-322.10.1056/NEJMoa1603827
- 47. von Scholten BJ, Hansen TW, Goetze JP, Persson F, Rossing P. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. J Diabetes Complications. 2015;29:670-674.10.1016/j.jdiacomp.2015.04.004
- 48. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326.10.1056/NEJMoa1307684
- 49. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067-2076.10.1016/S0140-6736(14)62225-X
- 50. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373:232-242.10.1056/NEJMoa150135226052984
- 51. Cernea S, Cahn A, Raz I. Saxagliptin for the treatment of diabetes — a focus on safety. Expert Opin Drug Saf. 2016;15:697-707.10.1517/14740338.2016.115967526923222
- 52. Udell JA, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015;38:696-705.10.2337/dc14-185025552421
- 53. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117-2128.10.1056/NEJMoa150472026378978
- 54. Rajasekeran H, Lytvyn Y, Cherney DZ. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int. 2016;89:524-526.10.1016/j.kint.2015.12.03826880444
- 55. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care. 2016;39:1108-1114.10.2337/dc16-033027289126
- 56. Carubelli V, Lombardi C, Gorga E, Ravera A, Metra M, Mentz RJ. Cardiorenal Interactions. Heart Fail Clin. 2016;12:335-347.10.1016/j.hfc.2016.03.00227371511